Drug Discovery · Boston, MA · Founded 2022 · Privately Held (backing)
Developer of a generative biology medicine technology intended to accelerate new possibilities in drug discovery and development. Superluminal Medicines is based in Boston, MA and was founded in 2022. It was valued at $576 million at its Series B in Sep 2026, the last priced event on record. It has raised $158 million across 4 recorded rounds; the latest was a $65.5 million Series B in Sep 2026.
PMV mark · valuation
$576.3M
Oct 2026
Priced at
its Series B
Sep 2026
Total raised
$157.7M
Last round
Series B
Sep 2026
Team — not yet on record
No current team members for Superluminal Medicines are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Superluminal Medicines with a free account
·The post-money valuation on its round
·The complete investor list: 12 names
·Watch Superluminal Medicines: the Monday email on marks, rounds and moves
